-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Agendia, Inc.
, a global leader in breast cancer precision oncology, announced today that it has obtained positive results from the analysis of samples from the NSABP B-42 trial using its 70-gene MammaPrint ® test .
The above results were presented orally at the 2021 American Society of Clinical Oncology ( ASCO ) annual meeting .
® ASCO
The abstract is titled "The Use of the 70 Gene MammaPrint Test in the NRG Oncology/NSABP B-42 Trial to Predict the Benefits of Prolonged Letrozole Therapy (ELT) ", presented by Dr.
Priya Rastogi of NSABP, detailing the retrospective analysis of 1,866 samples It is estimated that these samples are about half of the original experimental tissue samples and are representative of the entire cohort .
The 70- gene MammaPrint test is used to predict the benefit of extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial
Patients with genomic low-risk results are stratified into ultra-low-risk and low-risk groups
.
The benefits of prolonged endocrine therapy are mainly seen in the low-risk (non-ultra-low) group
Dr.
Adam Brufsky, MD, co-director of the Women’s Cancer Center at Maggie Women’s Hospital, UPMC Hillman Cancer Center, said: “By stratifying patients outside of high-risk or low-risk, we can see greater differences in genomic characteristics
.
And so on.
The original NSABP B-42 trial was designed to determine whether ELT can improve DFS after five years of standard therapy based on aromatase inhibitors.
Nearly 4,000 postmenopausal women with stage I-IIIA hormone receptor-positive breast cancer were enrolled.
After about five years of treatment with inhibitors or tamoxifen followed by aromatase inhibitors, no lesions were seen
.
Each group in the trial was randomly assigned to receive five years of letrozole (an endocrine therapy commonly used in adjuvant therapy) or a placebo
William Audeh, MD, Chief Medical Officer of Agendia, said: "We are very pleased to contribute to the results of the NSABP B-42 trial.
The important observation is that the use of MammaPrint for genome qualitative detection is most likely to benefit from and those who are unlikely to benefit from The ELT cohort
.
The above data is very valuable for clinicians and women with breast cancer.
At ASCO 2021, Agendia also reported additional data on ultra-low risk thresholds from the MINDACT study, as well as more data sets from the company’s pioneering FLEX filing library, which is a large sample using whole transcriptome sequencing, Prospective, observational breast cancer research
.
FLEX has long been committed to increasing the representation of diverse groups and data in clinical trials.
Leave a message here
